文献速递产科生殖医学

妊娠早期补充孕激素预防不明原因复发性流产女性流产:随机对照试验的系统评价与Meta分析

Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials.
PubMed 文献 · Fertil Steril · 2016-11-22

该系统评价与Meta分析纳入10项随机对照试验共1586例有不明原因复发性流产史的女性,比较妊娠早期补充孕激素与安慰剂或不治疗。汇总数据显示孕激素组流产风险降低(RR 0.72,95%CI 0.53-0.97),活产率升高(RR 1.07,95%CI 1.02-1.15),早产、新生儿死亡和胎儿生殖器异常无统计学显著差异。作者认为孕激素可能降低复发性流产发生率且对胎儿似乎安全,但难以推荐给药途径和剂量。

要点

  • 孕激素组流产风险低于对照组(RR 0.72,95%CI 0.53-0.97)。
  • 孕激素组活产率高于对照组(RR 1.07,95%CI 1.02-1.15)。
  • 合成孕激素而非天然孕酮与复发性流产风险降低相关。

核心结论

  • 妊娠早期补充孕激素可能降低不明原因复发性流产女性的流产发生率,且对胎儿似乎安全。
  • 合成孕激素(包括每周肌注17-羟孕酮己酸酯)而非天然孕酮与复发性流产风险降低相关。
  • 鉴于纳入研究的局限性,难以推荐孕激素治疗的途径和剂量,需进一步开展孕酮类型、剂量和给药途径的头对头试验。

研究设计与样本

  • 系统评价与Meta分析,通过检索电子数据库识别随机对照试验。
  • 纳入妊娠早期补充孕激素(干预组)与安慰剂或不治疗(对照组)比较的随机对照试验,对象为有复发性流产史的女性。
  • 共分析10项试验包括1586例复发性流产女性;8项研究使用安慰剂对照且为双盲。
  • 干预方面,2项随机对照试验使用天然孕酮,其余8项研究使用孕激素:甲羟孕酮、孕酮环戊基烯醇醚、地屈孕酮或17-羟孕酮己酸酯。

主要发现

  • 汇总10项试验数据显示,妊娠早期且16周前随机分入孕激素组的不明原因复发性流产女性,复发性流产风险低于未使用孕激素者(RR 0.72,95%CI 0.53-0.97)。
  • 孕激素组活产率高于对照组(RR 1.07,95%CI 1.02-1.15)。
  • 早产无统计学显著差异(RR 1.09,95%CI 0.71-1.66)。
  • 新生儿死亡无统计学显著差异(RR 1.80,95%CI 0.44-7.34)。
  • 胎儿生殖器异常无统计学显著差异(RR 1.68,95%CI 0.22-12.62)。

关键数值与推荐

  • 主要结局为流产发生率,汇总指标以相对危险度(RR)及95%置信区间(CI)报告。
  • 孕激素组与对照组的复发性流产风险:RR 0.72,95%CI 0.53-0.97。
  • 孕激素组与对照组的活产率:RR 1.07,95%CI 1.02-1.15。
  • 孕激素组与对照组的早产:RR 1.09,95%CI 0.71-1.66。
  • 孕激素组与对照组的新生儿死亡:RR 1.80,95%CI 0.44-7.34;胎儿生殖器异常:RR 1.68,95%CI 0.22-12.62。

临床怎么用

  • 作者认为补充孕激素可能降低复发性流产发生率,且对胎儿似乎安全。
  • 作者指出合成孕激素(包括每周肌注17-羟孕酮己酸酯)而非天然孕酮与复发性流产风险降低相关。
  • 作者表示鉴于纳入Meta分析研究的局限性,难以推荐孕激素治疗的途径和剂量。
  • 作者提出需进一步开展孕酮类型、剂量和给药途径的头对头试验。

局限性

  • 作者指出鉴于纳入Meta分析研究的局限性,难以推荐孕激素治疗的途径和剂量。
  • 作者提出需进一步开展孕酮类型、剂量和给药途径的头对头试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether treatment with progestogens in the first trimester of pregnancy would decrease the incidence of miscarriage in women with a history of unexplained recurrent miscarriage. DESIGN: Systematic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Women with a history of unexplained recurrent miscarriage. INTERVENTION(S): Randomized, controlled trials were identified by searching electronic databases. We included randomized, controlled trials comparing supplementation with progestogens (i.e., intervention group) in the first trimester of pregnancy with control (either placebo or no treatment) in women with a history of recurrent miscarriage. All types of progestogens, including natural P and synthetic progestins, were analyzed. MAIN OUTCOME MEASURE(S): The primary outcome was the incidence of miscarriage. The summary measures were reported as relative risk (RR) with 95% confidence interval (CI). RESULT(S): Ten trials including 1,586 women with recurrent miscarriage were analyzed. Eight studies used placebo as control and were double-blind. Regarding the intervention, two RCTs used natural P, whereas the other eight studies used progestins: medroxyprogesterone, cyclopentylenol ether of progesterone, dydrogesterone, or 17-hydroxyprogesterone caproate. Pooled data from the 10 trials showed that women with a history of unexplained recurrent miscarriage who were randomized to the progestogens group in the first trimester and before 16 weeks had a lower risk of recurrent miscarriage (RR 0.72, 95% CI 0.53-0.97) and higher live birth rate (RR 1.07, 95% CI 1.02-1.15) compared with those who did not. No statistically significant differences were found in the other secondary outcomes, including preterm birth (RR 1.09, 95% CI 0.71-1.66), neonatal mortality (RR 1.80, 95% CI 0.44-7.34), and fetal genital abnormalities (RR 1.68, 95% CI 0.22-12.62). CONCLUSION(S): Our findings provide evidence that supplementation with progestogens may reduce the incidence of recurrent miscarriages and seem to be safe for the fetuses. Synthetic progestogens, including weekly IM 17-hydroxyprogesterone caproate, but not natural P, were associated with a lower risk of recurrent miscarriage. Given the limitations of the studies included in our meta-analysis, it is difficult to recommend route and dose of progestogen therapy. Further head-to-head trials of P types, dosing, and route of administration are required.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Saccone G, Schoen C, Franasiak JM, et al. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 2016. PMID: 27887710. doi:10.1016/j.fertnstert.2016.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。